According to Marinus Pharmaceuticals's latest financial reports the company's current revenue (TTM ) is โฌ27.14 Million. In 2023 the company made a revenue of โฌ28.03 Million an increase over the revenue in the year 2022 that were of โฌ23.75 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2024 (TTM) | โฌ28.79 M | 2.71% |
2023 | โฌ28.03 M | 18.02% |
2022 | โฌ23.75 M | 75.3% |
2021 | โฌ13.54 M | 870.08% |
2020 | โฌ1.39 M | |
2019 | N/A | |
2018 | N/A | |
2017 | N/A | |
2016 | N/A | |
2015 | N/A | |
2014 | N/A | |
2013 | N/A |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
![]() AcelRx Pharmaceuticals
ACRX | โฌ0.56 M | -97.93% | ๐บ๐ธ USA |
![]() Eagle Pharmaceuticals
EGRX | โฌ0.22 B | 718.51% | ๐บ๐ธ USA |
![]() Endo International
ENDPQ | โฌ1.73 B | 6,292.67% | ๐ฎ๐ช Ireland |
![]() Supernus Pharmaceuticals
SUPN | โฌ0.57 B | 2,022.92% | ๐บ๐ธ USA |